Antimicrobial susceptibilities of canine Clostridium difficile and Clostridium perfringens isolates to commonly utilized antimicrobial drugs.
Clostridium difficile and Clostridium perfringens are anaerobic, Gram-positive bacilli that are common causes of enteritis and enterotoxemias in both domestic animals and humans. Both organisms have been associated with acute and chronic large and small bowel diarrhea, and acute hemorrhagic diarrheal syndrome in the dog. The objective of this study was to determine the in vitro antimicrobial susceptibilities of canine C. difficile and C. perfringens isolates in an effort to optimize antimicrobial therapy for dogs with clostridial-associated diarrhea. The minimum inhibitory concentrations (MIC) of antibiotics recommended for treating C. difficile (metronidazole, vancomycin) and C. perfringens-associated diarrhea in the dog (ampicillin, erythromycin, metronidazole, tetracycline, tylosin) were determined for 70 canine fecal C. difficile isolates and 131 C. perfringens isolates. All C. difficile isolates tested had an MIC of <or=1 for both metronidazole and vancomycin. Ninety-five percent (124/131) of C. perfringens isolates tested had an MIC for ampicillin of <or=0.125 microg/ml. Two C. perfringens isolates had an MIC of >or=256 microg/ml for both erythromycin and tylosin. A third C. perfringens isolate had an MIC of 32 microg/ml for metronidazole. Based on the results of this study, ampicillin, erythromycin, metronidazole, and tylosin appear to be effective antibiotics for the treatment of C. perfringens-associated diarrhea, although resistant strains do exist. However, because there is limited information regarding breakpoints for veterinary anaerobes, and because intestinal concentrations are not known, in vitro results should be interpreted with caution.
Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California, 2108 Tupper Hall, Davis, CA 95616, USA. slmarks@ucdavis.edu
Stanley L
SL
Marks
Elizabeth J
EJ
Kather
D000667:Ampicillin / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D016360:Clostridioides difficile / Q000187:drug effects* / Q000302:isolation & purification; D003015:Clostridium Infections / Q000188:drug therapy / Q000382:microbiology / Q000662:veterinary*; D003016:Clostridium perfringens / Q000187:drug effects* / Q000302:isolation & purification; D003967:Diarrhea / Q000188:drug therapy / Q000382:microbiology / Q000662:veterinary; D004283:Dog Diseases / Q000188:drug therapy / Q000382:microbiology*; D004285:Dogs; D004917:Erythromycin / Q000494:pharmacology / Q000627:therapeutic use; D008795:Metronidazole / Q000494:pharmacology / Q000627:therapeutic use; D008826:Microbial Sensitivity Tests / Q000662:veterinary; D013752:Tetracycline / Q000494:pharmacology / Q000627:therapeutic use; D015645:Tylosin / Q000494:pharmacology / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D008795:Metronidazole; D004917:Erythromycin; D000667:Ampicillin; D013752:Tetracycline; D015645:Tylosin